A Phase I Study Of JS015 in Patients With Advanced Solid Tumors

Summary

This is a Phase I open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of JS015 in patients with advanced solid tumors. The Recommended dose for phase II trial （RP2D） was determined based on the safety, pharmacokinetics, and initial efficacy data of the dose escalation and extension.

Timeline

Start

2023-02-13

Primary completion

2024-02-23

Completion

2024-03-26

Drugs

Indications